Research Digest / Synthetic Melanocortin Peptide / MT-II

Melanotan 2 has been studied in Phase I human trials and a broad preclinical literature — here is what the published research has actually measured.

An independent editorial digest of the mechanism, trial outcomes, pharmacokinetics, safety observations, and open scientific questions in the Melanotan 2 literature. Every quantitative claim is cited.

Read the research summary Open the dosage record
Risograph illustration of a cyclic peptide ring above a stylized cross-section of skin and melanocytes
COVER · FIG. 00

What the Melanotan 2 literature has established

Melanotan 2 (MT-II) is a fully synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was designed at the University of Arizona in the early 1990s as a truncated, cyclized, and potency-optimized version of the native 13-amino-acid peptide. The complete sequence is Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2 — a lactam bridge between the Asp5 and Lys10 side chains constrains the backbone into a conformation that binds melanocortin receptors with substantially higher affinity and metabolic stability than linear alpha-MSH.

The research literature on Melanotan 2 spans four primary lines of inquiry: melanogenesis stimulation, erectile function via MC4R, appetite modulation through central melanocortin circuits, and a pharmacovigilance record that documents adverse events in unregulated use. No regulatory agency has approved MT-II for any human indication. The published human data derive from two small early-phase trials — Dorr 1996 (n=3)[1] and Wessells 1998/2000 (n=10–20)[2][3] — and a body of post-market case reports.

The melanogenesis finding came first. In the 1996 Dorr Phase I trial, subcutaneous MT-II at 0.01–0.025 mg/kg produced measurable skin darkening in two of three healthy volunteers within two weeks.[1] The sexual function signal was serendipitous: male subjects in tanning trials reported spontaneous erections, which led to a dedicated MC4R erectile-axis research program.[18] In a double-blind crossover study of 20 men with erectile dysfunction, MT-II at 0.025 mg/kg produced clinically measurable erections in 17 of 20 subjects in the absence of sexual stimulation, with mean tip rigidity exceeding 80% for 41 minutes, compared against placebo.[3]

The compound's pharmacological breadth — it binds MC1R, MC3R, MC4R, and MC5R — is both the source of its research interest and a key reason no clinical development program has advanced to Phase III. Non-selective receptor engagement creates a wide adverse-effect profile. The melanocortin receptor binding profile is the starting point for understanding why MT-II produces such diverse effects across different tissues and organ systems.

Melanotan 2 Tanning Research: Melanogenesis Without UV

The mechanism underlying MT-II's tanning effect is MC1R activation. MC1R is expressed on melanocytes throughout the epidermis; when stimulated by alpha-MSH or its synthetic analogs, MC1R couples to adenylyl cyclase via Gs, elevates intracellular cAMP, activates PKA, and upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis. This pathway drives eumelanin production independent of ultraviolet radiation.

In the 1996 Dorr Phase I study, five low subcutaneous doses administered over ten days produced reflectance-measured pigmentation increases in two of three subjects within two weeks.[1] Fitzpatrick skin type substantially influenced response; subjects with lighter baseline pigmentation showed greater relative change. The 2021 Gilhooley qualitative study of 623 online discussion entries from 205 MT-II users identified cosmetic tanning and fitness competition preparation as the primary stated motivations for use, and documented risks including pigmented skin lesions and product contamination.[7]

MC1R activation can also drive proliferation of melanocytes in individuals with pre-existing dysplastic nevi or melanoma predisposition. A case series documented eruptive dysplastic nevi following MT-II use in a patient with a personal history of dysplastic nevi[20]; a second case report described histologically confirmed melanoma in a 20-year-old woman who self-injected MT-II while also using tanning beds.[9]

Editorial illustration of the melanogenesis pathway as flowing pigment granules through a skin layer
Abstract depiction of the melanogenesis pathway — eumelanin synthesis driven by MC1R/cAMP/tyrosinase activation.

What Is Melanotan 2?

Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Developed at the University of Arizona under Victor Hruby and Mac Hadley, it was engineered to be more potent, more metabolically stable, and more receptor-active than the native 13-amino-acid peptide. Its molecular weight is 1024.2 Da.

Alpha-MSH itself is produced from the precursor polypeptide POMC (pro-opiomelanocortin) and activates melanocortin receptors to regulate pigmentation, energy balance, and sexual function. MT-II reproduces and amplifies this signaling, binding MC1R, MC3R, MC4R, and MC5R with high affinity — a broader receptor coverage than alpha-MSH's primary MC1R/MC4R targeting.

MT-II is not derived from biological sources. It is produced entirely by solid-phase peptide synthesis; the cyclic structure is introduced chemically via a Asp5–Lys10 lactam bridge during synthesis. The compound has not been approved for human use by any regulatory authority worldwide.

Mol. Weight 1024.2 Da
Plasma t½ ~1 hour
Receptors MC1R–MC5R
Status Unapproved

What Has Melanotan 2 Been Studied For?

Published research has studied Melanotan 2 for four primary applications: melanogenesis stimulation (UV-independent tanning), erectile dysfunction via MC4R activation in the hypothalamic-limbic axis[2][3], appetite and body weight modulation through central MC3R/MC4R melanocortin circuits[5][6], and neuroprotection in peripheral nerve injury models.[13]

The sexual-function research program grew directly from tanning-trial observations, as documented in Hadley's 2005 historical account.[18] The MC4R erectile response was subsequently confirmed in double-blind controlled human trials. The appetite and body-weight effects were characterized in rodent models; chronic central melanocortin activation produced persistent body mass reduction and a 3-fold increase in brown adipose tissue thermogenesis in a 40-day rat study.[5]

None of these applications have reached regulatory approval for MT-II specifically. The related compound bremelanotide (PT-141), a direct metabolite of MT-II, received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women — representing the clinical translation of the MC4R sexual-function pathway first characterized with MT-II.

Read the full mechanism summary Safety observations

Chemical Origin of Melanotan 2

Melanotan 2 is a fully synthetic compound. It is not extracted from melanocytes, skin, or any biological tissue. The full sequence — Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2 — is built by solid-phase peptide synthesis, in which amino acids are assembled sequentially on a solid resin support and the cyclizing lactam bridge is introduced chemically.

The design rationale was to increase both potency and metabolic stability over native alpha-MSH. The D-Phe7 substitution (a non-natural amino acid stereoisomer) resists proteolytic cleavage; the cyclic backbone reduces conformational flexibility, locks the bioactive conformation, and further impedes enzymatic degradation. The result is a peptide with a plasma half-life on the order of one hour — approximately sixty times longer than the ~10–15 minute half-life of linear alpha-MSH in rodent plasma.

Full research-grade preparation uses lyophilized (freeze-dried) powder that is reconstituted in sterile water or bacteriostatic saline according to published research protocols.